Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls

European Journal of Clinical Investigation

Volumn 32, Issue 4, 2002, Pages 259-264

  Mackness, B ^a   Durrington, P N ^a   Boulton, A J M ^a   Hine, D ^a   Mackness, M I ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Atherosclerosis; High density lipoprotein; Oxidation; Paraoxonase; Type 1 diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ISOENZYME;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; ESTERASES; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; POLYMORPHISM, GENETIC;

EID: 0036995784     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00977.x     Document Type: Article

References (31)

1. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letts 1991;286:152-4.
2. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
3. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.
4. Watson AD, Berliner JA, Hama SY, Du La, BN, Fault KF, Fogelman AM et al. Protective effect of high density lipoprotein associated paraoxonase - Inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995;96:2882-91.
5. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al. N: Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective active of human paraoxonase alloenzymes Q and R. Arterioscl Thromb Vasc Biol 1998;10:1617-24.
6. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffmann A et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510-7.
7. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7.
8. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Carelinez CJ, Castellani LW et al. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997;99:2005-19.
9. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Comm 1998;247:443-6.
10. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM et al. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidised low-density lipoprotein. J Clin Invest 1995;95:774-82.
11. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001;354:1-7.
12. Macphee C, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA et al. Lipoprotein - associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338:479-87.
13. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J et al. Lipoprotein - associated phospholipase A2 as an independent predictor of coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
14. Mackness MI, Durrington PN, Mackness B. How HDL protects against the effects of lipid peroxidation. Curr Option Lipidol 2000;11:383-8.
15. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts 1998;423:57-60.
16. Mackness B, Davies GK, Turkie W, Lee W, Roberts DH, Hill E et al. Paraoxonase status in coronary heart disease - are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7.
17. Durrington PN, Mackness B, Mackness MI. Paraoxonase and Atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
18. Hunt JV, Wolff SP. Oxidative glycation and free radial production: a causal mechanism of diabetic complications. Free Rad Res Comms 1991;12-13:115-23.
19. Hunt JV, Smith CCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modifications by glucose. Diabetes 1990;39:1420-4.
20. Abbott CA, Mackness MI, Kumar S, Boulton AJM, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-8.
21. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuashia B et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-9.
22. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Mashimto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000;48:1400-5.
23. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-9.
24. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives. influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001;155:229-35.
25. World Health Organisation Expert Committee on Diabetes Mellitus. Second Report. WHO Technical report series no. 646. Geneva: WHO;1980.
26. Mackness MI & Durrington PN. Lipoprotein Analysis for Clinical Studies. In: Converse, CA, Skinner ER, editors. Lipoprotein Analysis: a Practical Approach. Oxford: IRL Press;1992.pp.1-42.
27. Hedrick CC, Thrope SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-20.
28. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-9.
29. Durrington PN. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta 1980;104:11-23.
30. Araki S, Makita Y, Canani L, Ng D, Warram JM, Krolewski AS. Polymorphisms of the human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type 1 diabetes mellitus. Diabetologia 2000;43:1540-3.
31. Kao Y-L, Donaghue K, Chan A, Knight J, Silink M. A varaiant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 1998;83:2589-92.